Ronald Levy, MD
Academic Appointments
- Professor, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Lymphoma Clinic 875 Blake Wilbur Dr Clinic C Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Personal Information Tel (650) 725-6452Alternate Contact Adam Schetky Administrator Email Tel Work 650-725-6452Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Lymphoma
- Lymphoma
- Non-Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma - Medical Oncology
- Burkitt's Lymphoma
- Burkitt's Lymphoma - Medical Oncology
Honors and Awards
- King Faisal International Prize, King Faisal Foundation (2009)
- Member, National Academy of Sciences (2008)
- di Villiers International Achievement Award, Leukemia and Lymphoma Society (2007)
- Member, Institute of Medicine (2007)
- Damashek Prize, American Society of Hematology (2004)
- Jeffrey A. Gottlieb Memorial Award, M.D. Anderson Cancer Center (2003)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (1979) |
| Fellowship: | Stanford University School of Medicine CA (1973) |
| Residency: | Massachusetts General Hospital MA (1970) |
| Internship: | Massachusetts General Hospital MA (1969) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1973) |
| Medical Education: | Stanford University School of Medicine CA (1968) |
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Our research concentrates on the study of malignant lymphoma and tumors of the immune system using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Receptor molecules present on the surface of tumor cells transmit signals for regulation of cell growth. These receptors include the immunoglobulin molecule on B cell tumors and the T cell receptor on T cell tumors. Questions the lab is currently addressing include:
1. Can a clue to the pathogenesis of lymphoma be derived from a study of their antigen receptors?
2. Can new treatments for lymphoma be developed by targeting receptors with monoclonal antibodies?
3. Can vaccines be developed which can induce an immune response in the host against the receptors on their own tumor?
Clinical Trials
- Recruiting Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy
- Recruiting Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
- Not Recruiting Efficacy and Safety Study or Fostamatinib Disodium Tablets to Treat B-cell Lymphoma
- Not Recruiting Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
- Recruiting A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Publications
- Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013; (9): 1604-11
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013; (8): 1367-76
- A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci U S A. 2012; (36): 14526-31
- Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res. 2012; (5): 1239-47
- CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol. 2012; (3): 795-803
- Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012; (5): 511-27
Help
Trial Administration